Memantine For Prevention Research Articles

CO104 Efficacy of Memantine in Preventing Neurocognitive Dysfunction Induced By Radiation Therapy in Patients with Brain Metastases: A Systematic Review of Clinical Trials

Neurocognitive impairment affects about 50-90% of brain metastases patients who receive radiation therapy. However, literature search revealed that memantine had potential to prevent neurocognitive impairments induced by radiation therapy. However, due to lack of comprehensive data on memantine in prevention of neurocognitive impairments following radiation therapy, we conduct this systematic review to gather the safety and efficacy data of memantine therapy in prevention of neurocognitive dysfunction induced by radiation therapy in brain metastases patients.

Memantine for Prevention of Cognitive Decline in Patients With Breast Cancer

Memantine for Prevention of Cognitive Decline in Patients With Breast Cancer

Effect of memantine on post-operative cognitive dysfunction after cardiac surgeries: a randomized clinical trial

BackgroundPost-operative cognitive dysfunction (POCD) is an important complication of cardiac surgeries. Glutamate plays a critical role in physiologic and pathologic conditions in the brain. Due to the role of glutamate in ischemia, this study is designed to identify the effect of memantine in prevention of POCD early and late after cardiac surgeries.MethodsIn this randomized clinical trial, 172 patients with ages 45–75 years old who underwent elective cardiac surgery were enrolled. For patients in memantine group, 5 mg of memantine per day administered at least 48 h before surgery and increased to 10 mg per day during the first 24 h after surgery and continued for 3 months. A brief Wechsler memory test (WMT) was administered before, three to 5 days after, and 3 months after surgery for both groups.ResultsBoth groups demonstrate standard pattern of cognitive dysfunction after surgery and in follow up. Pre- and post-operative WMT score showed significant improvement in memantine compared to control group (P < 0.001) both in unadjusted and adjusted with confounding factor analysis. Unadjusted pre-, post-operative, and follow up WMT score improved significantly after 3 months in memantine group (P = 0.006).ConclusionPre-operative administration of memantine protects patients from POCD following cardiac surgeries. In addition, it improves cognitive function 3 months after surgery.Trial registrationThe trial was registered in the Iranian Registry of Clinical Trials (registration number: IRCT201303168698N12).Graphical abstractMemantin effect on POCD.